Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18744281 | 1.00 | KDM4E (0.65) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL19194546 | 1.00 | KDM4E (0.65) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL18744480 | 0.90 | KDM4E (0.64) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL6583746 | 0.90 | KDM4E (0.78) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL13744576 | 0.84 | ALDH1A1 (0.70) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL17297788 | 0.84 | ALDH1A1 (0.70) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL17297978 | 0.84 | ALDH1A1 (0.70) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL20749660 | 0.83 | KDM4E (0.68) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL19194519 | 0.83 | KDM4E (0.68) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 | |
| SCHEMBL3130725 | 0.82 | KDM4E (0.72) | KDM4EALDH1A1CHRNB2CHRNA4OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180208591-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2018-07-26 | — | — | US | disclosed |
| US-9701666-B2 | 1,4-pyridone bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208591-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, PAICS, CYP4B1 | KDM4E 1189/4885ALDH1A1 594/4885CHRNB2 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.